Kura Oncology to Participate in Bank of America Securities Healthcare Conference
Rhea-AI Summary
Kura Oncology (Nasdaq: KURA) will participate in the Bank of America Securities 2026 Healthcare Conference on May 13, 2026. Management is scheduled for a fireside chat at 6:00 p.m. ET / 3:00 p.m. PT. A live webcast and archived replay will be available on the company Investors website.
Positive
- None.
Negative
- None.
News Market Reaction – KURA
In the May 6 session, KURA gained 2.91%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 04 | Inducement option grants | Neutral | +5.5% | New employee stock options totaling 133,750 shares at $8.77 exercise price. |
| Apr 17 | Clinical data update | Positive | +8.3% | Darlifarnib plus cabozantinib showed robust activity in ccRCC patients. |
| Apr 09 | Conference presentation | Neutral | +0.7% | Planned IKCS Europe 2026 presentation of updated FIT-001 RCC data. |
| Mar 06 | Inducement option grants | Neutral | +5.3% | Inducement options for four new employees totaling 44,700 shares at $8.68. |
| Mar 05 | Earnings and update | Positive | -0.5% | Q4 and 2025 results with KOMZIFTI approval, $2.1M revenue and strong cash. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including clinical updates and routine grants, has often been followed by positive price reactions, while one earnings release saw a slight negative move.
Over the last six months, Kura’s news flow has included inducement option grants, positive clinical data for darlifarnib combinations, and 2025 earnings and pipeline updates. Several routine items, such as stock option grants on Mar 2, 2026 and May 1, 2026, were followed by 5.29% and 5.47% gains, respectively. A favorable RCC data readout on Apr 17, 2026 coincided with an 8.28% rise, while the detailed Q4 and full-year 2025 report on Mar 5, 2026 saw a modest -0.47% reaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Bank of America Securities 2026 Healthcare Conference. Kura management is scheduled to participate in a fireside chat at 6:00 p.m. ET / 3:00 p.m. PT on May 13, 2026.
The live webcast and archived replay of the event may be accessed on the Investors section of the Company’s website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
